VWR (NASDAQ: VWR) and Nevro (NYSE:NVRO) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
This table compares VWR and Nevro’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares VWR and Nevro’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VWR||$4.51 billion||0.97||$148.20 million||$1.14||29.17|
|Nevro||$228.50 million||9.99||-$31.77 million||($1.45)||-53.15|
VWR has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than VWR, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
96.7% of VWR shares are owned by institutional investors. 35.5% of VWR shares are owned by insiders. Comparatively, 9.1% of Nevro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for VWR and Nevro, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
VWR currently has a consensus price target of $32.00, suggesting a potential downside of 3.76%. Nevro has a consensus price target of $99.71, suggesting a potential upside of 29.38%. Given Nevro’s stronger consensus rating and higher possible upside, analysts clearly believe Nevro is more favorable than VWR.
VWR beats Nevro on 9 of the 13 factors compared between the two stocks.
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
Receive News & Ratings for VWR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR and related companies with MarketBeat.com's FREE daily email newsletter.